VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALXO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALXOALX Oncology Holdings Inc.
$0.97$131M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALXOCash Flow

ALX Oncology Holdings Inc. (ALXO) Cash Flow Statement

8Y historyFree accessUpdated daily

Free cash flow remained negative in every quarter, reaching -$34.8M in 2026Q2 with operating cash outflow at 1.93 times net loss, suggesting cash burn is outpacing accounting losses and no dividends or buybacks offset the drain.

Income StatementBalance SheetCash FlowRatios

ALXO Cash Flow Statement

Annual statement

ALXO Cash Flow Statement

ALX Oncology Holdings Inc. (ALXO) cash flow statement — 8-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18
Cash from Operations-68.42M-84.14M-121.91M-130.36M-89.22M-68.1M-38.29M-14.25M-13.19M
Operating CF Margin %-------3239.34%-297.1%-638.12%
Operating CF Growth %110.33%30.98%6.48%-46.11%-31.02%-77.86%-168.71%-8.03%-
Net Income-80.57M-101.69M-134.85M-160.81M-123.48M-83.46M-45.74M-19.24M-13.73M
Depreciation & Amortization443K706K872K836K342K51K202K429K431K
Stock-Based Compensation10.79M12.58M27.09M26.27M23.84M13.91M5.44M297K269K
Deferred Taxes000000000
Other Non-Cash Items174K3.93M-2.6M-4.96M228K5.42M1.57M11K0
Working Capital Changes739K336K-12.43M8.3M9.85M-4.03M247K4.26M-159K
Change in Receivables000000536K396K-932K
Change in Inventory000000000
Change in Payables-2.59M421K-4.02M458K4.51M3.29M-3.74M2.98M-269K
Cash from Investing-68.04M82.59M86.26M44.66M-235.42M-4.92M610K-353K-653K
Capital Expenditures-181K-212K-447K-1.27M-1.43M-666K-31K-353K-653K
CapEx % of Revenue------2.62%7.36%31.59%
Acquisitions0000233.99K0000
Investments---------
Other Investing173K000-233.99K-4.26M641K00
Cash from Financing148.61M362K30.82M59.29M9.86M2.47M462.88M15.36M1K
Debt Issued (Net)-1.99M-1.36M-827K-388K9.61M-281K05.92M0
Equity Issued (Net)142.65M1.73M31.64M58.89M903K2.75M472.94M9.43M-6K
Dividends Paid000000000
Share Repurchases31K0000000-6K
Other Financing7.95M00792K-655K0-10.05M10K7K
Net Change in Cash12.14M-1.19M-4.84M-26.42M-314.78M-70.55M425.2M755K-13.84M
Free Cash Flow-68.61M-84.35M-122.36M-131.64M-90.65M-73.02M-38.32M-14.6M-13.84M
FCF Margin %-------3241.96%-304.46%-669.71%
FCF Growth %29.59%31.06%7.05%-45.22%-24.14%-90.56%-162.43%-5.48%-
FCF per Share-0.49-1.57-2.35-3.06-2.23-1.81-0.96-0.67-0.63
FCF Conversion (FCF/Net Income)0.85x0.83x0.90x0.81x0.72x0.82x0.84x0.74x0.96x
Interest Paid0000011K427K00
Taxes Paid00000274K47K00

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetMixed
Cash FlowBurning
Top Statement Risk

Continued cash burn dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Operating Cash Burn Exceeds Reported Losses

According to ALXO's reported quarterly figures, operating cash outflow exceeded the net loss in several recent periods, with the ratio reaching 1.93 in 2026Q2, suggesting cash consumption is running ahead of accounting losses and warrants close monitoring.

In most quarters the ratio of operating cash flow to net income sits between 0.67 and 1.10, meaning the company burned slightly less cash than its accounting loss in some periods and more in others. The 2026Q2 spike to roughly 1.93 times the net loss, driven by a $34.7M operating outflow against an $18.0M net loss, is the most important data point and implies a substantial working capital or non-cash timing effect that the supplied data does not fully explain. Investors should monitor whether this divergence persists, since it would indicate the true cash runway is shorter than earnings alone suggest.

Free Cash Flow Deficit Narrowing Unevenly

Based on ALXO's reported figures, free cash flow remained negative in every quarter, improving from roughly -$38.1M in 2024Q1 to -$18.7M in 2026Q1 before worsening to -$34.8M in 2026Q2.

Because revenue is effectively absent, free cash flow margin is not meaningful and the analysis rests on absolute burn rates. The trend shows a clear reduction in quarterly burn over the two-year window, which aligns with the prior income statement finding of lower R&D spending. However, the 2026Q2 reversal to a burn near the 2024 peak suggests the improvement has not been linear and that quarterly volatility in working capital is material to the runway estimate.

Minimal Capital Intensity Confirms Asset-Light Model

As reported in financial statements, ALXO's capital expenditures remained below $150K in every quarter shown, with the largest outlay of $149.0K in 2024Q3, indicating a very light fixed-asset footprint.

Capital spending is negligible relative to operating cash outflows, so maintenance versus growth capex distinction carries little analytical weight for this company. Depreciation and amortization of roughly $150K to $240K per quarter is similarly small, consistent with a clinical-stage model that outsources manufacturing and trials. The implication is that cash burn is driven almost entirely by operating expenses rather than physical investment.

No Shareholder Returns, Dependence on External Funding

Based on ALXO's reported data, the company paid no dividends and conducted no share buybacks in any of the ten quarters, leaving external capital markets as the apparent source of funding for ongoing burn.

The absence of dividends and repurchases is expected for a pre-revenue biotechnology company and does not itself signal distress. The more relevant question is how the cumulative operating outflow exceeding $200M over this period has been financed, which the supplied cash flow data does not disclose. Investors should review the balance sheet and financing disclosures to assess remaining liquidity and the likelihood of future equity dilution.

Stock Compensation Masks True Cash Economics

According to reported figures, stock-based compensation of $2.1M to $7.3M per quarter is added back in operating cash flow, meaning the reported cash burn may understate the economic cost of employee equity pay.

Because SBC is a non-cash charge, it lowers net income without consuming cash, which can make the net loss appear larger than the cash burn in some periods. Here the operating cash outflow still exceeded the net loss in several quarters, so SBC does not fully explain the gap. Investors should recognize that continued equity compensation implies shareholder dilution, which represents a real economic cost not captured in the free cash flow figure.

ALXO — Frequently Asked Questions

Quick answers to the most common questions about buying ALXO stock.

How much cash does ALX Oncology Holdings Inc. (ALXO) generate from operations?

ALX Oncology Holdings Inc. (ALXO) generated $-84.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is ALX Oncology Holdings Inc.'s free cash flow?

ALX Oncology Holdings Inc. (ALXO) reported negative free cash flow of $84.4M in 2025, indicating capital requirements exceeded cash from operations.

What is ALX Oncology Holdings Inc.'s capital expenditure (CapEx)?

ALX Oncology Holdings Inc. (ALXO) spent $0.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.